556 related articles for article (PubMed ID: 31552549)
1. Neurofilament light chain in serum of adolescent and adult SMA patients under treatment with nusinersen.
Wurster CD; Steinacker P; Günther R; Koch JC; Lingor P; Uzelac Z; Witzel S; Wollinsky K; Winter B; Osmanovic A; Schreiber-Katz O; Al Shweiki R; Ludolph AC; Petri S; Hermann A; Otto M;
J Neurol; 2020 Jan; 267(1):36-44. PubMed ID: 31552549
[TBL] [Abstract][Full Text] [Related]
2. Neurofilament Levels in CSF and Serum in an Adult SMA Cohort Treated with Nusinersen.
Rich KA; Fox A; Yalvac M; Heintzman S; Tellez M; Bartlett A; Severyn S; Linsenmayer M; Kelly K; Reynolds J; Sterling GB; Weaver T; Rajneesh K; Pino MG; Arnold WD; Elsheikh B; Kolb SJ
J Neuromuscul Dis; 2022; 9(1):111-119. PubMed ID: 34776417
[TBL] [Abstract][Full Text] [Related]
3. Cerebrospinal Fluid and Clinical Profiles in Adult Type 2-3 Spinal Muscular Atrophy Patients Treated with Nusinersen: An 18-Month Single-Centre Experience.
Milella G; Introna A; D'Errico E; Fraddosio A; Scaglione G; Morea A; Ucci M; Ruggieri M; Mastrapasqua M; Megna M; Puntillo F; Simone IL
Clin Drug Investig; 2021 Sep; 41(9):775-784. PubMed ID: 34389971
[TBL] [Abstract][Full Text] [Related]
4. Nusinersen for adults with spinal muscular atrophy.
Arslan D; Inan B; Kilinc M; Bekircan-Kurt CE; Erdem-Ozdamar S; Tan E
Neurol Sci; 2023 Jul; 44(7):2393-2400. PubMed ID: 36854931
[TBL] [Abstract][Full Text] [Related]
5. Safety and Treatment Effects of Nusinersen in Longstanding Adult 5q-SMA Type 3 - A Prospective Observational Study.
Walter MC; Wenninger S; Thiele S; Stauber J; Hiebeler M; Greckl E; Stahl K; Pechmann A; Lochmüller H; Kirschner J; Schoser B
J Neuromuscul Dis; 2019; 6(4):453-465. PubMed ID: 31594243
[TBL] [Abstract][Full Text] [Related]
6. Neurochemical markers in CSF of adolescent and adult SMA patients undergoing nusinersen treatment.
Wurster CD; Günther R; Steinacker P; Dreyhaupt J; Wollinsky K; Uzelac Z; Witzel S; Kocak T; Winter B; Koch JC; Lingor P; Petri S; Ludolph AC; Hermann A; Otto M
Ther Adv Neurol Disord; 2019; 12():1756286419846058. PubMed ID: 31205491
[TBL] [Abstract][Full Text] [Related]
7. Neurofilament Heavy Chain and Tau Protein Are Not Elevated in Cerebrospinal Fluid of Adult Patients with Spinal Muscular Atrophy during Loading with Nusinersen.
Totzeck A; Stolte B; Kizina K; Bolz S; Schlag M; Thimm A; Kleinschnitz C; Hagenacker T
Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31671515
[TBL] [Abstract][Full Text] [Related]
8. Nusinersen treatment and cerebrospinal fluid neurofilaments: An explorative study on Spinal Muscular Atrophy type 3 patients.
Faravelli I; Meneri M; Saccomanno D; Velardo D; Abati E; Gagliardi D; Parente V; Petrozzi L; Ronchi D; Stocchetti N; Calderini E; D'Angelo G; Chidini G; Prandi E; Ricci G; Siciliano G; Bresolin N; Comi GP; Corti S; Magri F; Govoni A
J Cell Mol Med; 2020 Mar; 24(5):3034-3039. PubMed ID: 32032473
[TBL] [Abstract][Full Text] [Related]
9. NFL is a marker of treatment response in children with SMA treated with nusinersen.
Olsson B; Alberg L; Cullen NC; Michael E; Wahlgren L; Kroksmark AK; Rostasy K; Blennow K; Zetterberg H; Tulinius M
J Neurol; 2019 Sep; 266(9):2129-2136. PubMed ID: 31123861
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the neurofilament light chain as a biomarker in children with spinal muscular atrophy treated with nusinersen.
Seo G; Kim S; Byun JC; Kwon S; Lee YJ
Brain Dev; 2023 Nov; 45(10):554-563. PubMed ID: 37541812
[TBL] [Abstract][Full Text] [Related]
11. Serum creatine kinase and creatinine in adult spinal muscular atrophy under nusinersen treatment.
Freigang M; Wurster CD; Hagenacker T; Stolte B; Weiler M; Kamm C; Schreiber-Katz O; Osmanovic A; Petri S; Kowski A; Meyer T; Koch JC; Cordts I; Deschauer M; Lingor P; Aust E; Petzold D; Ludolph AC; Falkenburger B; Hermann A; Günther R
Ann Clin Transl Neurol; 2021 May; 8(5):1049-1063. PubMed ID: 33792208
[TBL] [Abstract][Full Text] [Related]
12. Risdiplam improves subjective swallowing quality in non-ambulatory adult patients with 5q-spinal muscular atrophy despite advanced motor impairment.
Brakemeier S; Lipka J; Schlag M; Kleinschnitz C; Hagenacker T
J Neurol; 2024 May; 271(5):2649-2657. PubMed ID: 38358553
[TBL] [Abstract][Full Text] [Related]
13. Prospective Cohort Study of Nusinersen Treatment in Adults with Spinal Muscular Atrophy.
Yeo CJJ; Simeone SD; Townsend EL; Zhang RZ; Swoboda KJ
J Neuromuscul Dis; 2020; 7(3):257-268. PubMed ID: 32333595
[TBL] [Abstract][Full Text] [Related]
14. Real-World Data from Nusinersen Treatment for Patients with Later-Onset Spinal Muscular Atrophy: A Single Center Experience.
Mendonça RH; Polido GJ; Matsui C; Silva AMS; Solla DJF; Reed UC; Zanoteli E
J Neuromuscul Dis; 2021; 8(1):101-108. PubMed ID: 33074187
[TBL] [Abstract][Full Text] [Related]
15. Comparison of neurofilament light and heavy chain in spinal muscular atrophy and amyotrophic lateral sclerosis: A pilot study.
Li JY; Dai Y; Sun XH; Ren HT; Shen DC; Yang XZ; Liu MS; Cui LY
Brain Behav; 2023 May; 13(5):e2997. PubMed ID: 37070132
[TBL] [Abstract][Full Text] [Related]
16. Intrathecal nusinersen treatment after ventriculo-peritoneal shunt placement: A case report focusing on the neurofilament light chain in cerebrospinal fluid.
Tozawa T; Kasai T; Tatebe H; Shiomi K; Nishio H; Tokuda T; Chiyonobu T
Brain Dev; 2020 Mar; 42(3):311-314. PubMed ID: 31889567
[TBL] [Abstract][Full Text] [Related]
17. Cerebrospinal fluid proteomic profiling in nusinersen-treated patients with spinal muscular atrophy.
Kessler T; Latzer P; Schmid D; Warnken U; Saffari A; Ziegler A; Kollmer J; Möhlenbruch M; Ulfert C; Herweh C; Wildemann B; Wick W; Weiler M
J Neurochem; 2020 Jun; 153(5):650-661. PubMed ID: 31903607
[TBL] [Abstract][Full Text] [Related]
18. Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy.
Mercuri E; Darras BT; Chiriboga CA; Day JW; Campbell C; Connolly AM; Iannaccone ST; Kirschner J; Kuntz NL; Saito K; Shieh PB; Tulinius M; Mazzone ES; Montes J; Bishop KM; Yang Q; Foster R; Gheuens S; Bennett CF; Farwell W; Schneider E; De Vivo DC; Finkel RS;
N Engl J Med; 2018 Feb; 378(7):625-635. PubMed ID: 29443664
[TBL] [Abstract][Full Text] [Related]
19. Nusinersen treatment significantly improves hand grip strength, hand motor function and MRC sum scores in adult patients with spinal muscular atrophy types 3 and 4.
De Wel B; Goosens V; Sobota A; Van Camp E; Geukens E; Van Kerschaver G; Jagut M; Claes K; Claeys KG
J Neurol; 2021 Mar; 268(3):923-935. PubMed ID: 32935160
[TBL] [Abstract][Full Text] [Related]
20. Later efficacy of nusinersen treatment in adult patients with spinal muscular atrophy: A retrospective case study with a median 4-year follow-up.
Funato M; Kino A; Iwata R; Yumioka M; Yamashita K; Urui C; Uno R; Kondo E; Morioka E; Ogawa Y; Kawamura A; Kusukawa T; Minatsu H
Brain Dev; 2024 Jan; 46(1):62-67. PubMed ID: 37657961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
